Market Research

Cancer Vaccines Market Size– By Technology, By Type, By Indication, By End User - Regional Outlook, Competitive Strategies and Segment Forecast to 2032

Best Price Guarantee Length Publisher Published Date SKU
from $4,250 242 Pages SPER Market Research Pvt. Ltd. December, 2022 SPER18001346
Best Price Guarantee
Price from $4,250
Length 242 Pages
Publisher SPER Market Research Pvt. Ltd.
Published Date December, 2022
SKU SPER18001346

Cancer Vaccines Market Size– By Technology, By Type, By Indication, By End User - Regional Outlook, Competitive Strategies and Segment Forecast to 2032


Global Cancer Vaccines Market Overview:

According to SPER Market Research, the Global Cancer Vaccines Market is estimated to reach USD 20.09 billion by 2032 with a CAGR of 12.82%. Vaccines are medications that boost the body's immune system to defend it from foreign substances. Cancer vaccines are medicines that act as biological response modifiers. Foreign bodies are destroyed by an activated immune system. Vaccines function on the theory of memorizing foreign particles and preventing illness caused by these foreign particles when they invade again.

Impact of COVID-19 on the Global Cancer Vaccines Market

The market for Global Cancer Vaccines Market production and distribution firms have been impacted to a limited amount by COVID-19, owing to shutdowns in various COVID-19 afflicted nations and an increase in the number of healthcare professionals becoming ill in the of the pandemic, resulting in low supply. The pandemic has hampered cancer vaccine manufacturing as well as the import and export of raw materials and completed goods owing to shutdowns in various COVID-19-affected nations.

Scope of the Report:

Market size available for years 2019-2032
Base year considered 2021
Forecast period 2022-2032

Segments covered By Technology, By Type, By Indication, By End User

Regions covered North America, Europe, Asia Pacific, Latin America, Middle East and Africa

Companies Covered Aduro Biotech, Advantagene, Advaxis, Agenus, Altor BioScience, Argos Therapeutics, Dendreon, GlaxoSmithKline, Onco Thyreon, Oncovir, Oxford BioMedical.

Global Cancer Vaccines Market Segmentation:

By Technology:Based on the Technology, Global Cancer Vaccines Market is segmented as; Dendritic Cells (DC) Cancer Vaccines, Recombinant Cancer Vaccines, Antigen/Adjuvant Cancer Vaccines, Viral Vector & DNA Cancer Vaccines.

By Region:Due to rising cancer fatalities, North America is expected to account for the highest proportion of the global cancer vaccines market. Due to growing government initiatives, businesses focusing more on the India vaccine technology market, and growing immunisation programmes by the World Health Organization and GAVI, Asia Pacific is anticipated to have the most growth.


1. Introduction
1.1. Scope of the report
1.2. Market segment analysis
2. Research Methodology
2.1 Research data source
2.1.1 Secondary data
2.1.2 Primary data
2.1.3 SPER’s internal database
2.1.4 Premium insight from KOL’s
2.2 Market size estimation
2.2.1 Top-down and Bottom-up approach
2.3 Data triangulation
3. Executive Summary
4. Market Dynamics
4.1. Driver, Restraint, Opportunity and Challenges analysis
4.1.1 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges
4.2. COVID-19 Impacts of the Global Cancer Vaccines Market
5. Market variables and outlook
5.1. SWOT analysis
5.1.1 Strengths
5.1.2 Weaknesses
5.1.3 Opportunities
5.1.4 Threats
5.2. PESTEL analysis
5.2.1 Political landscape
5.2.2 Economic landscape
5.2.3 Social landscape
5.2.4 Technological landscape
5.2.5 Environmental landscape
5.2.6 Legal landscape
5.3. PORTER’S five forces analysis
5.3.1 Bargaining power of suppliers
5.3.2 Bargaining power of Buyers
5.3.3 Threat of Substitute
5.3.4 Threat of new entrant
5.3.5 Competitive rivalry
5.4.Heat map analysis
6. Global Cancer Vaccines Market, By Technology, 2019-2032 (USD Million)
6.1. Antigen/Adjuvant Cancer Vaccines
6.2. Dendritic Cells (DC) Cancer Vaccines
6.3. Recombinant Cancer Vaccines
6.4. Viral Vector & DNA Cancer Vaccines
7. Global Cancer Vaccines Market, By Type, 2019-2032 (USD Million)
7.1. Preventive Cancer Vaccines
7.2. Therapeutic Cancer Vaccines
8. Global Cancer Vaccines Market, By Indication, 2019-2032 (USD Million)
8.1. Cervical Cancer
8.2. Prostate Cancer
8.3. Others.
9. Global Cancer Vaccines Market, By End User, 2019-2032 (USD Million)
9.1. Pediatrics
9.2. Adults
10. Global Cancer Vaccines Market, By Region, 2019-2032 (USD Million)
10.1. North America
10.1.1. Canada
10.1.2. Mexico
10.1.3. United States
10.2. Europe
10.2.1. France
10.2.2. Germany
10.2.3. Italy
10.2.4. Rest of Europe
10.2.5. Spain
10.2.6. United Kingdom
10.3. Asia-Pacific
10.3.1. Australia
10.3.2. China
10.3.3. India
10.3.4. Japan
10.3.5. Rest of Asia-Pacific
10.3.6. South Korea
10.4. South America
10.4.1. Brazil
10.4.2. Argentina
10.4.3. Rest of South America
10.5. Middle East & Africa
10.5.1. Kingdom of Saudi Arabia
10.5.2. United Arab Emirates
10.5.3. Rest of Middle East & Africa
11. Company Profiles
11.1. Aduro Biotech
11.1.1. Company details
11.1.2. Financial outlook
11.1.3. Product summary
11.1.4. Recent developments
11.2. Advantagene
11.2.1. Company details
11.2.2. Financial outlook
11.2.3. Product summary
11.2.4. Recent developments
11.3. Advaxis
11.3.1. Company details
11.3.2. Financial outlook
11.3.3. Product summary
11.3.4. Recent developments
11.4. Agenus
11.4.1. Company details
11.4.2. Financial outlook
11.4.3. Product summary
11.4.4. Recent developments
11.5. Altor BioScience
11.5.1. Company details
11.5.2. Financial outlook
11.5.3. Product summary
11.5.4. Recent developments
11.6. Argos Therapeutics
11.6.1. Company details
11.6.2. Financial outlook
11.6.3. Product summary
11.6.4. Recent developments
11.7. Dendreon
11.7.1. Company details
11.7.2. Financial outlook
11.7.3. Product summary
11.7.4. Recent developments
11.8. GlaxoSmithKline
11.8.1. Company details
11.8.2. Financial outlook
11.8.3. Product summary
11.8.4. Recent developments
11.9. OncoThyreon
11.9.1. Company details
11.9.2. Financial outlook
11.9.3. Product summary
11.9.4. Recent developments
11.10. Oncovir
11.10.1. Company details
11.10.2. Financial outlook
11.10.3. Product summary
11.10.4. Recent developments
11.11. Oxford BioMedical
11.11.1. Company details
11.11.2. Financial outlook
11.11.3. Product summary
11.11.4. Recent developments
11.12. Prsima BioMed
11.12.1. Company details
11.12.2. Financial outlook
11.12.3. Product summary
11.12.4. Recent developments
11.13. Sotio
11.13.1. Company details
11.13.2. Financial outlook
11.13.3. Product summary
11.13.4. Recent developments
11.14. Transgene
11.14.1. Company details
11.14.2. Financial outlook
11.14.3. Product summary
11.14.4. Recent developments
11.15. Ubivac
11.15.1. Company details
11.15.2. Financial outlook
11.15.3. Product summary
11.15.4. Recent developments
11.16. Vaccinogen
11.16.1. Company details
11.16.2. Financial outlook
11.16.3. Product summary
11.16.4. Recent developments
11.17. Vaxon Biotech
11.17.1. Company details
11.17.2. Financial outlook
11.17.3. Product summary
11.17.4. Recent developments

$4,250
$7,450

Research Assistance

US: 800.298.5699
Int'l: +1.240.747.3093
Live help
Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Other tasks

Cookie Settings